Background: Sickle cell disease is a genetic hemoglobinopathy that often presents as a vaso-occlusive crisis. Moyamoya disease, which is a complication of sickle cell disease, is a progressive, occlusive cerebrovascular disorder that affects the circle of Willis and the arteries that feed it (1).
We believed that end-organ damage was caused by the vaso-occlusive crisis, and the patient had exchange transfusion of 7 units of packed red blood cells and hemodialysis. On hospital day 6, intraerythrocyte inclusions were incidentally seen on peripheral blood smear ( Figure) . A malaria thick smear and polymerase chain reaction assay confirmed the diagnosis of P falciparum infection. With no history of travel and inclusions of mostly nonsickled cells on the peripheral smear, transfusion-transmitted malaria was considered probable. This case was reported to the Centers for Disease Control and Prevention (CDC).
Although CDC guidelines recommend intravenous quinidine as first-line treatment of severe malaria (2) , this therapy was avoided because of a prolonged rate-corrected QT interval on electrocardiography. Instead, we administered intravenous artesunate for 7 days. The patient improved, was extubated on hospital day 10, and was transferred out of the intensive care unit. He was discharged on hospital day 42. The CDC conducted a retrospective review of transfusion records, including the exchange transfusion received during the hospital stay, and determined that the patient received a transfusion contaminated with P falciparum 3 weeks before admission.
Discussion: Transfusion-transmitted malaria is uncommon in the United States (3, 4) . However, persons who require many blood transfusions, such this patient, are at increased risk and may have severe complications that can be falsely attributed to the underlying disease.
Hyoscyamine for a Slow Ventricular Response During Atrial Fibrillation
Background: Atrial fibrillation typically presents with tachycardia; atrial fibrillation with bradycardia is much less common. Bradycardia may be due to increased vagal tone, drugs affecting the atrioventricular node, or conduction system disease. Symptomatic bradycardia caused by conduction system disease is often treated with a pacemaker, because medications are not usually effective. Atropine, glycopyrrolate, hyoscyamine, and other anticholinergic drugs inhibit receptors that are present in smooth and cardiac muscle, the sinoatrial and atrioventricular node, and the exocrine glands (1-3). These drugs are often used to inhibit gastrointestinal propulsion and decrease urinary bladder contractions and secretions of the pharynx, stomach, trachea, and bronchus. They are also used preoperatively to block cardiac vagal inhibitory reflexes during intubation and anesthesia induction.
Objective: To alert clinicians that an anticholinergic drug may be used in selected patients who would otherwise require a pacemaker for a slow ventricular response during atrial fibrillation.
Case Report: A 98-year-old man with a long-term indwelling urinary catheter, dementia, atrial fibrillation, and metastatic prostate cancer presented to the emergency department with recurrent syncope and bradycardia. Medications were amlodipine, dabigatran, and enzalutamide. Blood pressure was 72/40 mm Hg, heart rate was 35 beats/min, and electrocardiography documented atrial fibrillation with a slow ventricular response and right bundle branch block (Figure 1) . After 0.5 mg of intravenous atropine was administered, the heart rate and blood pressure increased to 50 beats/min and 118/73 mm Hg, respectively. Physical examination revealed an irregularly irregular rhythm but no murmurs, jugular venous distention, or edema. Results of abdominal and neurologic examinations were consistent with the patient's known diagnoses. He remained in atrial fibrillation overnight with a heart rate between 40 and 50 beats/min.
We considered placing a leadless pacemaker or increasing the baseline heart rate with medication and ultimately decided to try medication therapy first because of the patient's comorbidities. We administered intravenous glycopyrrolate, 0.1 mg, and the heart rate increased from 50 to 73 beats/min and remained so for 30 minutes. We then administered 0.125 mg of sublingual, immediate-release hyoscyamine and observed a similar but prolonged response. The patient did not develop tachyarrhythmia overnight and was discharged the next day with a resting heart rate between 70 and 80 beats/min while receiving the same type and dose of hyoscyamine 4 times daily. When the patient returned 4 weeks later for routine follow-up, he had experienced no syncope and repeated electrocardiography showed a resting heart rate of 73 beats/min ( Figure 2) .
Discussion: To our knowledge, this is the first report of hyoscyamine or any other anticholinergic drug being used to avoid pacemaker placement in a patient with symptoms caused by a slow ventricular response during atrial fibrillation. This patient was a poor candidate for a pacemaker because of dementia, which would prevent him from following the activity restrictions required after pacemaker placement to avoid lead dislodgement, including arm raising and weight bearing on the side of pacemaker implantation for 2 to 4 weeks. The patient also used a walker, which involves upper-extremity weight bearing and can strain the ipsilateral pectoralis major, increasing the risk for lead dislodgement. Moreover, the urinary catheter would prevent him from experiencing urine retention, which is a common adverse effect of hyoscyamine in such patients.
Additional studies are necessary to determine whether this patient's successful outcome can be realized more generally. Clinicians may want to attempt this approach in patients with atrial fibrillation who have a slow ventricular response and would qualify for a pacemaker but have comorbidities that make this intervention less desirable. We advise administering a test dose of 0.1 mg of intravenous glycopyrrolate in these patients, because this agent has a relatively short halflife. The heart rate should increase at least 20% within 10 minutes of administration. If the test is successful, we recommend sublingual hyoscyamine, 0.125 mg 4 times daily, for longerterm treatment and believe that this dose can be increased to 1.5 mg/d if needed. 
OBSERVATION: BRIEF RESEARCH REPORT An Independent Evaluation of the Accuracy and Usability of Electronic Adherence Monitoring Devices
Background: Approximately 50% of patients are nonadherent to their medications, and this is a primary cause of treatment failure, morbidity, and mortality (1, 2). As a result, it is associated with an estimated $300 billion in potentially ¶ Because only 2 devices were operational, 2 devices were tested instead of 3. ** Before use, the EAMD is programmed with the scheduled times of medication administration (or times the EAMD should be opened). The EAMD does not register additional openings. After the EAMD is opened at the scheduled time, the EAMD does not record additional subsequent openings until the next scheduled medication administration. † † The EAMD records the date but not the time of openings, precluding the calculation of the primary measure of accuracy or mean discrepancy. ‡ ‡ Because this EAMD records only the date and not the time of openings, this measure of accuracy was defined as the number of EAMD registrations recorded on the same date as those on the paper test protocol out of the number of scheduled openings per the protocol (n = 25).
avoidable U.S. health care costs each year (1, 2). Increasing adherence may improve health outcomes and reduce costs even more so than the advent of new medical treatments (1, 3) . However, such efforts have been limited by the lack of objective measures of adherence (3). Electronic adherence monitoring devices (EAMDs) are the most objective and preferred measurement strategy for clinical practice and research but lack independently obtained (versus manufacturerprovided) data on accuracy.
Objective: To assess the accuracy of commercially available EAMDs and help clinicians and researchers select the optimal EAMD based on their needs and goals (4) .
Methods and Findings: This study was exempt from institutional review board review. PubMed/MEDLINE, CINAHL, PsycINFO, and Scopus were searched to identify all EAMDs included in published studies of medication adherence. To maximize the likelihood that all relevant EAMDs were identified, coauthors who are experts in adherence also provided a list of EAMDs with which they were familiar. The systematic review identified 12 EAMDs, and the experts identified an additional 10. Of the 22 EAMDs, 15 were available for purchase and 10 were successfully obtained (3 manufacturers did not reply, 1 manufacturer refused to sell their EAMD, and 1 EAMD was cost-prohibitive [>$500]).
Four of each EAMD were obtained, with 3 devices tested according to a 21-day protocol reflecting a twice-daily medication prescribed 7 days per week. Each protocol simulated 4 adherence patterns: perfect adherence (EAMD opened at 100% of prescribed doses), nonadherence: additional doses (EAMD opened at 5 randomly selected times in addition to prescribed doses [150% of prescribed doses]), nonadherence: missed doses (EAMD opened at 50% of prescribed doses), and device nonuse (EAMD opened at 0% of prescribed doses) (5). All patterns except for device nonuse were tested over 1 of 3 workweeks (Monday through Friday). The EAMDs were not opened on weekends to simulate device nonuse. Each protocol included 25 scheduled openings. Three protocols were generated using a counterbalanced design in which each of the 3 EAMDs of a given model was simultaneously tested for a different adherence pattern.
The date and time of each opening were recorded by the first author on a paper form. A second investigator independently recorded the date and time of a random 10% of openings (intraclass correlation, 1.00). The primary measure of EAMD accuracy was the number of EAMD-registered openings out of 25 that fell within 120 seconds of the date and time recorded on the paper form (4). Table 1 defines additional measures of accuracy. Characteristics of EAMDs (dimensions, data transmission, reminders, notifications, and data access) were obtained from publicly available information. Capacity (defined as the number of 10-mm round tablets and 18-mm oval caplets held by each EAMD) was assessed independently by 2 investigators.
All 3 tested devices of 7 EAMD types registered at least 24 of 25 openings within 120 seconds of the date and time recorded by the investigators. The average discrepancy between the EAMD-registered time and the date and time recorded by the investigators for each device ranged from 3 to Table 2 includes features relevant to usability. Discussion: In this independent evaluation, 7 of 10 EAMDs accurately registered at least 24 of 25 openings. Among these, the EAMD that is "best" for a given clinical program or research study depends on the characteristics of the patient population (medication number and size, medication schedule, and patient preferences). Selecting an EAMD with features that align with patient characteristics may increase patient acceptability and uptake. In addition, clinicians and researchers should consider the degree to which EAMD features are consistent with the patients' geographic location (for example, EAMDs requiring cellular connectivity may not function in areas with limited service), the degree to which EAMD features are consistent with the clinical or research goal of EAMD use (for example, efforts to passively monitor adherence may preclude the use of EAMDs with reminders), and their budget. The costs of EAMDs vary substantially, and pricing information unfortunately is not publicly available for all devices. Interested users thus may need to independently solicit quotes and should note that some manufacturers will only provide quotes that are confidential and/or after obtaining information about budget availability.
This study has limitations. Not all available EAMDs were tested, and testing took place in a controlled laboratory without activating all available features. Evaluating the full functionality, usability, and connectivity of EAMDs will require future study.
In summary, many EAMDs accurately assess medication adherence behavior. To identify the most appropriate EAMD, we encourage clinicians and researchers to consider the characteristics of their patient population and their clinical or research goals. 
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